These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38713520)

  • 21. Microdystrophin Gene Addition Significantly Improves Muscle Functionality and Diaphragm Muscle Histopathology in a Fibrotic Mouse Model of Duchenne Muscular Dystrophy.
    Cernisova V; Lu-Nguyen N; Trundle J; Herath S; Malerba A; Popplewell L
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Muscle regeneration affects Adeno Associated Virus 1 mediated transgene transcription.
    Mollard A; Peccate C; Forand A; Chassagne J; Julien L; Meunier P; Guesmia Z; Marais T; Bitoun M; Piétri-Rouxel F; Benkhelifa-Ziyyat S; Lorain S
    Sci Rep; 2022 Jun; 12(1):9674. PubMed ID: 35690627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-Dependent Microdystrophin Expression Enhancement in Cardiac Muscle by a Cardiac-Specific Regulatory Element.
    Malerba A; Sidoli C; Lu-Nguyen N; Herath S; Le Heron A; Abdul-Razak H; Jarmin S; VandenDriessche T; Chuah MK; Dickson G; Popplewell L
    Hum Gene Ther; 2021 Oct; 32(19-20):1138-1146. PubMed ID: 33765840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical potential of microdystrophin as a surrogate endpoint.
    Boehler JF; Brown KJ; Beatka M; Gonzalez JP; Donisa Dreghici R; Soustek-Kramer M; McGonigle S; Ganot A; Palmer T; Lowie C; Chamberlain JS; Lawlor MW; Morris CA
    Neuromuscul Disord; 2023 Jan; 33(1):40-49. PubMed ID: 36575103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of Therapeutic Potential of a Dual AAV Approach for Duchenne Muscular Dystrophy.
    Albini S; Palmieri L; Dubois A; Bourg N; Lostal W; Richard I
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice.
    Koo T; Popplewell L; Athanasopoulos T; Dickson G
    Hum Gene Ther; 2014 Feb; 25(2):98-108. PubMed ID: 24191945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microutrophin expression in dystrophic mice displays myofiber type differences in therapeutic effects.
    Banks GB; Chamberlain JS; Odom GL
    PLoS Genet; 2020 Nov; 16(11):e1009179. PubMed ID: 33175853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping.
    Goyenvalle A; Babbs A; Wright J; Wilkins V; Powell D; Garcia L; Davies KE
    Hum Mol Genet; 2012 Jun; 21(11):2559-71. PubMed ID: 22388933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy.
    Birch SM; Lawlor MW; Conlon TJ; Guo LJ; Crudele JM; Hawkins EC; Nghiem PP; Ahn M; Meng H; Beatka MJ; Fickau BA; Prieto JC; Styner MA; Struharik MJ; Shanks C; Brown KJ; Golebiowski D; Bettis AK; Balog-Alvarez CJ; Clement N; Coleman KE; Corti M; Pan X; Hauschka SD; Gonzalez JP; Morris CA; Schneider JS; Duan D; Chamberlain JS; Byrne BJ; Kornegay JN
    Sci Transl Med; 2023 Jan; 15(677):eabo1815. PubMed ID: 36599002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Restoration of all dystrophin protein interactions by functional domains in trans does not rescue dystrophy.
    Gardner KL; Kearney JA; Edwards JD; Rafael-Fortney JA
    Gene Ther; 2006 May; 13(9):744-51. PubMed ID: 16307000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.
    Bengtsson NE; Hall JK; Odom GL; Phelps MP; Andrus CR; Hawkins RD; Hauschka SD; Chamberlain JR; Chamberlain JS
    Nat Commun; 2017 Feb; 8():14454. PubMed ID: 28195574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury.
    Liu M; Yue Y; Harper SQ; Grange RW; Chamberlain JS; Duan D
    Mol Ther; 2005 Feb; 11(2):245-56. PubMed ID: 15668136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. rAAV6-microdystrophin rescues aberrant Golgi complex organization in mdx skeletal muscles.
    Percival JM; Gregorevic P; Odom GL; Banks GB; Chamberlain JS; Froehner SC
    Traffic; 2007 Oct; 8(10):1424-39. PubMed ID: 17714427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Social stress is lethal in the mdx model of Duchenne muscular dystrophy.
    Razzoli M; Lindsay A; Law ML; Chamberlain CM; Southern WM; Berg M; Osborn J; Engeland WC; Metzger JM; Ervasti JM; Bartolomucci A
    EBioMedicine; 2020 May; 55():102700. PubMed ID: 32192914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy.
    Shin JH; Pan X; Hakim CH; Yang HT; Yue Y; Zhang K; Terjung RL; Duan D
    Mol Ther; 2013 Apr; 21(4):750-7. PubMed ID: 23319056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of the cardiac sodium channel Nav1.5 by utrophin in dystrophin-deficient mice.
    Albesa M; Ogrodnik J; Rougier JS; Abriel H
    Cardiovasc Res; 2011 Feb; 89(2):320-8. PubMed ID: 20952415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein-Anchoring Therapy of Biglycan for Mdx Mouse Model of Duchenne Muscular Dystrophy.
    Ito M; Ehara Y; Li J; Inada K; Ohno K
    Hum Gene Ther; 2017 May; 28(5):428-436. PubMed ID: 27485975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice.
    Zhou Y; Zhang C; Xiao W; Herzog RW; Han R
    Nat Commun; 2024 Jul; 15(1):6141. PubMed ID: 39034316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.